Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Detemir vs NPH in Type 2 Diabetes
NCT00383877Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2006
- Primary completion
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin detemir in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycosylated Hemoglobin A1c at 20 weeks. Started Sep 2006; status: completed.
02
Drugs
insulin detemir
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00383877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00383877.